



Express Mail No. ERS17841652 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Brines *et al.* Confirmation No.: 5119
Application No.: 09/717,057 Art Unit: 1647
Filed: November 21, 2000 Examiner: DeBerry, Regina M.
For: MODULATION OF EXCITABLE Attorney Docket No.: 10165-010-999
TISSUE FUNCTION BY
PERIPHERALLY ADMINISTERED
ERYTHROPOIETIN

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references FF to FK listed on the attached revised form PTO-1449. This application is a divisional of U.S. Serial No. 09/547,220, filed April 11, 2000, which claims benefit of U.S. provisional application no. 60/118,030, filed April 13, 1999 (expired). A copy of each of the identified references is provided herewith.

Identification of the listed references are not to be construed as an admission of the Applicants or Attorneys for the Applicants that such references are available as "prior art" against the subject application.

The Applicants respectfully request that the Examiner review the foregoing references

10/07/2005 HDESTA1 00000002 09717057

02 FC:1806

180.00 OP

and that the reference be made of record in the file history of the application.


This Supplemental Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. A credit card form is attached providing for the \$180.00 fee for the filing of the IDS in accordance with 37 C.F.R 1.17(p).

Respectfully submitted,

Date: October 5, 2005

By: Frederick J. Hamble 42,623
Frederick J. Hamble (Reg. No.)

712 Kitchawan Road
Ossining, NY 10562
(914) 762-7586



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known	
				Application Number	09/717,057
				Filing Date	November 21, 2000
				First Named Inventor	Brines
				Art Unit	1647
				Examiner Name	R. Deberry
Sheet	1	of	1	Attorney Docket Number	10165-010-999

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	FF	LU et al., Erythropoietin enhances Neurogenesis and Restores Spatial Memory in Rats After Traumatic Brain Injury, Journal of Neurotrauma, 2005, 1011-1017, 22-9		T ²
	FG	MOGENSEN et al., Pharmacology, Biochemistry, and Behavior, 2004, 381-390, 77		
	FH	KUMRAL et al., Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia rat, Behavioral Brain Research, 2004, 77-86, 153		
	FI	Ehrenreich, Erythropoietin: a candidate compound for neuroprotection in schizophrenia, Molecular Psychiatry, 2003, 1-13.		
	FJ	VAN DER MEER et al., JACC, 2005, 125-133, 46-1.		
	FK	KESWANI et al., A Novel Endogenous Erythropoietin Mediated Pathway Prevents Axonal Degeneration, ANN Neurol, 2004, 815-826, 56.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.